These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28893136)

  • 41. Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer.
    Desilets A; Repetto M; Drilon A
    Clin Transl Med; 2024 Oct; 14(10):e70017. PubMed ID: 39402859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
    Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
    Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lorlatinib: First Global Approval.
    Syed YY
    Drugs; 2019 Jan; 79(1):93-98. PubMed ID: 30604291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Different Types of
    He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
    Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
    [No Abstract]   [Full Text] [Related]  

  • 45. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
    Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
    J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
    Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
    J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations.
    Drilon A; Horan JC; Tangpeerachaikul A; Besse B; Ou SI; Gadgeel SM; Camidge DR; van der Wekken AJ; Nguyen-Phuong L; Acker A; Keddy C; Nicholson KS; Yoda S; Mente S; Sun Y; Soglia JR; Kohl NE; Porter JR; Shair MD; Zhu V; Davare MA; Hata AN; Pelish HE; Lin JJ
    Cancer Discov; 2023 Mar; 13(3):598-615. PubMed ID: 36511802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
    EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
    Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
    Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A molecular dynamics investigation into the mechanisms of alectinib resistance of three ALK mutants.
    He M; Li W; Zheng Q; Zhang H
    J Cell Biochem; 2018 Jul; 119(7):5332-5342. PubMed ID: 29323742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
    PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Zheng J; Cao H; Li Y; Rao C; Zhang T; Luo J; Lv D; Zhu Y; Zhou J; Zhou J
    Lung Cancer; 2020 Sep; 147():130-136. PubMed ID: 32702569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-guided identification of potent inhibitors of ROS1 kinase for therapeutic development against non-small cell lung cancer.
    Khan MS; Altwaijry N; Al-Bagmi MS; Alafaleq NO; Alokail MS; Shahwan M; Shamsi A
    J Biomol Struct Dyn; 2024 May; 42(8):3837-3847. PubMed ID: 37254309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.
    Moro-Sibilot D; Cozic N; Pérol M; Mazières J; Otto J; Souquet PJ; Bahleda R; Wislez M; Zalcman G; Guibert SD; Barlési F; Mennecier B; Monnet I; Sabatier R; Bota S; Dubos C; Verriele V; Haddad V; Ferretti G; Cortot A; De Fraipont F; Jimenez M; Hoog-Labouret N; Vassal G
    Ann Oncol; 2019 Dec; 30(12):1985-1991. PubMed ID: 31584608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ROS1-rearranged Non-small Cell Lung Cancer.
    Giustini NP; Bazhenova L
    Thorac Surg Clin; 2020 May; 30(2):147-156. PubMed ID: 32327173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Choroidal metastasis response to crizotinib in a ROS1-rearranged NSCLC patient.
    Lu S; Azada MC; Ou SH
    Lung Cancer; 2015 Feb; 87(2):207-9. PubMed ID: 25558789
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.
    Chin LP; Soo RA; Soong R; Ou SH
    J Thorac Oncol; 2012 Nov; 7(11):1625-30. PubMed ID: 23070242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.
    Chong CR; Bahcall M; Capelletti M; Kosaka T; Ercan D; Sim T; Sholl LM; Nishino M; Johnson BE; Gray NS; Jänne PA
    Clin Cancer Res; 2017 Jan; 23(1):204-213. PubMed ID: 27370605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.